Invivyd (IVVD) Total Non-Current Liabilities (2020 - 2024)

Invivyd (IVVD) posted Total Non-Current Liabilities of $62.0 million for Q4 2024, down 21.31% on a QoQ basis from $78.8 million in Q3 2024, and up 21.49% year-over-year from $51.0 million in Q1 2024.

Invivyd (IVVD) Total Non-Current Liabilities (2020 - 2024) Analysis & Trends

Invivyd's Total Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $62.0 million for Q4 2024.

  • Quarterly Total Non-Current Liabilities rose 21.49% year-over-year to $62.0 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $62.0 million (up 21.49% YoY) and the FY2024 annual result came in at $62.0 million, up 21.49% from the prior year.
  • Total Non-Current Liabilities was $62.0 million for Q4 2024 at Invivyd, down from $78.8 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $96.9 million in Q1 2022 and bottomed at $13.1 million in Q4 2020.
  • A 5-year average of $50.8 million and a median of $49.2 million in 2022 frame the typical range for Total Non-Current Liabilities.
  • Annual changes were most pronounced in 2021 — Total Non-Current Liabilities jumped 374.4% — and 2022, when it plunged 56.18%.
  • Invivyd's Total Non-Current Liabilities stood at $13.1 million in 2020, then soared by 374.4% to $62.1 million in 2021, then tumbled by 56.18% to $27.2 million in 2022, then jumped by 87.57% to $51.0 million in 2023, then rose by 21.49% to $62.0 million in 2024.
  • Business Quant data shows IVVD's Total Non-Current Liabilities at $62.0 million in Q4 2024, $78.8 million in Q3 2024, and $36.7 million in Q2 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 4.45 Mn
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - 110.28 Mn
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - 19.49 Mn
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 1.98 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.35 Bn 37.35 Bn - 746.94 Mn
10 Invivyd 104.07 Mn -122.62 Mn 16.07 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2024 61.98 Mn
Sep 30, 2024 78.76 Mn
Jun 30, 2024 36.70 Mn
Mar 31, 2024 36.97 Mn
Dec 31, 2023 51.01 Mn
Sep 30, 2023 27.72 Mn
Dec 31, 2022 27.20 Mn
Sep 30, 2022 47.30 Mn
Jun 30, 2022 69.77 Mn
Mar 31, 2022 96.88 Mn
Dec 31, 2021 62.07 Mn
Dec 31, 2020 13.08 Mn